Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.

Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, Northfelt DW.

J Clin Pharmacol. 2010 Mar;50(3):268-75. doi: 10.1177/0091270009343699. Epub 2009 Oct 6.


Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

Herben VM, ten Bokkel Huinink WW, Schot ME, Hudson I, Beijnen JH.

Anticancer Drugs. 1998 Jun;9(5):411-8.


Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.

Clin Cancer Res. 1997 Aug;3(8):1245-52.


Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.

Clin Cancer Res. 1998 May;4(5):1153-8.


Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J, von Hoff DD.

Eur J Cancer. 1998 Jun;34(7):1030-5.


A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J.

Clin Cancer Res. 1999 Jan;5(1):69-75.


No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.

Zackrisson AL, Malmström H, Peterson C.

Eur J Clin Pharmacol. 2002 May;58(2):103-8. Epub 2002 Apr 5.


Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.

Clin Cancer Res. 2003 Sep 15;9(11):4092-100.


Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.

Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS.

Clin Cancer Res. 1999 Dec;5(12):3956-62.


Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ.

Cancer Res. 1994 Mar 1;54(5):1220-6.


A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL.

Gynecol Oncol. 2000 Aug;78(2):228-34.


A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

Wall JG, Burris HA 3rd, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, et al.

Anticancer Drugs. 1992 Aug;3(4):337-45.


Phase II study of oral topotecan in advanced non-small cell lung cancer.

White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S, Ross G, Ranson M.

Clin Cancer Res. 2000 Mar;6(3):868-73.


Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

Burris HA 3rd, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD.

Anticancer Drugs. 1994 Aug;5(4):394-402.


Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.

Zhou H, Choi L, Lau H, Bruntsch U, Vries EE, Eckhardt G, Oosterom AT, Verweij J, Schran H, Barbet N, Linnartz R, Capdeville R.

J Clin Pharmacol. 2000 Mar;40(3):275-83.


Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.

Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH.

Clin Cancer Res. 2009 Jul 1;15(13):4475-83. doi: 10.1158/1078-0432.CCR-08-3144. Epub 2009 Jun 16.


Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5.

Fields SZ, Igwemezie LN, Kaul S, Schacter LP, Schilder RJ, Litam PP, Himpler BS, McAleer C, Wright J, Barbhaiya RH, et al.

Clin Cancer Res. 1995 Jan;1(1):105-11.


Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.

Boucaud M, Pinguet F, Poujol S, Romieu G, Cupissol D, Astre C, Culine S, Bressolle F.

Eur J Cancer. 2001 Dec;37(18):2357-64.


Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.

Schaefer PL, Marks RS, Mahoney MR, Sloan JA, Bauman MD, Tazelaar HD, Kugler JW, Mailliard JA, Ebbert LP, Wiesenfeld M.

Am J Clin Oncol. 2003 Jun;26(3):236-40.


Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.

Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.

Cancer Res. 1993 Mar 1;53(5):1032-6.

Supplemental Content

Support Center